Heterozygous Familial Hypercholesterolemia Clinical Trials in Beijing, Beijing Municipality
2 recruitingBeijing, Beijing Municipality, China
Showing 1–2 of 2 trials
Recruiting
Phase 2Phase 3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC153 enrolled26 locationsNCT07058077
Recruiting
Phase 3
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Primary hypercholesterolemiaMetabolic DiseaseDyslipidemias+4 more
Hasten Biopharmaceutical Co., Ltd.210 enrolled18 locationsNCT06568471